- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05323747
Prospective Evaluation of a Commercially Available Hydrogel Spacer (BP-008)
September 15, 2025 updated by: BioProtect
Clinical Protocol for the Prospective Evaluation of a Commercially Available Hydrogel Spacer
Dosimetry efficacy evaluation of the hydrogel spacer
Study Overview
Detailed Description
Single arm study for evaluation of dosimetry following use of a commercially available hydrogel spacer implanted in 20 males undergoing radiotherapy to treat prostate cancer.
Study will utilize pre and post gel insertion CT images to determine the endpoints.
Study Type
Observational
Enrollment (Actual)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Campbell, California, United States, 95008
- Western Radiation Oncology
-
-
Nevada
-
Reno, Nevada, United States, 89521
- Northern Nevada Radiation Oncology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Prostate Cancer
Description
Inclusion Criteria:
- Males
- At lease 18 years of age
- Undergoing external beam or brachy radiation therapy with a hydrogel spacer
Exclusion Criteria:
- Invasive adenocarcinoma that is extracapsular and demonstrates posterior extension
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Radiation with Hydrogel Spacer
Males at least 18 years of age, who will be undergoing radiation therapy with a hydrogel spacer in place.
|
Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dosimetry changes
Time Frame: 1 month
|
Assessment of rectal radiation exposure as compared between rectal dose volume histograms calculated for pre and post Hydrogel Injection
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prostate to rectum spacing
Time Frame: 1 month
|
Prostate to rectum spacing measurement for evaluation of the perirectal distance post-hydrogel insertion
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 20, 2020
Primary Completion (Actual)
June 29, 2021
Study Completion (Actual)
February 8, 2022
Study Registration Dates
First Submitted
March 17, 2022
First Submitted That Met QC Criteria
April 5, 2022
First Posted (Actual)
April 12, 2022
Study Record Updates
Last Update Posted (Estimated)
September 16, 2025
Last Update Submitted That Met QC Criteria
September 15, 2025
Last Verified
April 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BP-008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.